Search
GW810781
go.drugbank.com/drugs/DB16032InvestigationalGW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).
Enapotamab vedotin
go.drugbank.com/drugs/DB16156InvestigationalEnapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors).
Fluorine F-18
go.drugbank.com/drugs/DB13134InvestigationalFluorine-18 is under investigation in clinical trial NCT00870974 (A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions).
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
GZ-389988
go.drugbank.com/drugs/DB16056InvestigationalGZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients
Tricaine
go.drugbank.com/drugs/DB11552ExperimentalVet approvedIt is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Desonide
go.drugbank.com/drugs/DB01260ApprovedInvestigationalA nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
Mixtures: APOLAR N, DESOLEX-NAtigotatug
go.drugbank.com/drugs/DB14831InvestigationalIt is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
ISO-1 F-18
go.drugbank.com/drugs/DB14900InvestigationalISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).
Omzotirome
go.drugbank.com/drugs/DB16046InvestigationalTRC150094 is under investigation in clinical trial NCT03254446 (Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension).